Bcl‐2 causes chemoresistance in sarcoma, and chemosensitivity to doxorubicin and cisplatin can be restored by the Bcl‐2 inhibitor ABT‐737 (van Oosterwijk et al., 2012). This evidence concerns the gene BCL2 and sarcoma.